Market closedNon-fractional

Denali Therapeutics/DNLI

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Ticker

DNLI

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South San Francisco, United States

Employees

375

DNLI Metrics

BasicAdvanced
$3.1B
Market cap
-
P/E ratio
-$0.98
EPS
1.36
Beta
-
Dividend rate
$3.1B
1.36
11.789
11.345
2.957
3.473
-8.70%
-11.33%
10.35
2.12
2.12
-7.19
191.13%
-66.02%
-4.58%
25.71%

What the Analysts think about DNLI

Analyst Ratings

Majority rating from 16 analysts.
Buy

DNLI Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$102M
-14.74%
Profit margin
0.00%
NaN%

DNLI Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.25%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$1.30
-$0.72
-$0.86
-$0.68
-
Expected
-$0.68
-$0.80
-$0.80
-$0.70
-$0.68
Surprise
-290.08%
-10.28%
6.94%
-3.25%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Denali Therapeutics stock?

Denali Therapeutics (DNLI) has a market cap of $3.1B as of July 04, 2024.

What is the P/E ratio for Denali Therapeutics stock?

The price to earnings (P/E) ratio for Denali Therapeutics (DNLI) stock is 0 as of July 04, 2024.

Does Denali Therapeutics stock pay dividends?

No, Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Denali Therapeutics dividend payment date?

Denali Therapeutics (DNLI) stock does not pay dividends to its shareholders.

What is the beta indicator for Denali Therapeutics?

Denali Therapeutics (DNLI) has a beta rating of 1.36. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Denali Therapeutics stock

Buy or sell Denali Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing